Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC

Phase 3177Lu-NYM032Positive

AI Analysis

Summary

Norroy Bioscience received regulatory clearance from China's NMPA to initiate a pivotal Phase III clinical trial of 177Lu-NYM032, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.

Clinical Trial Data

Phase

Phase III

Outcome Details

Regulatory clearance received from NMPA to initiate pivotal Phase III trial

Importance:7/10

Sentiment:

0.70

PSMA-targeted therapyradioligand therapyoncologyprostate cancerChinaregulatory approval

Related Companies

$BHIC $NHPAP $MDCE $CHHE $WXI

Read the original article

Published by PR Newswire Biotech on September 2, 2026 9:00 AM

Read Original